Patents by Inventor Philippe Reginault
Philippe Reginault has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8940894Abstract: The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula I: which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.Type: GrantFiled: May 10, 2013Date of Patent: January 27, 2015Assignee: AB ScienceInventors: Alain Moussy, Philippe Reginault, Francois Bellamy, Anne Lermet
-
Patent number: 8492545Abstract: The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula I: which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.Type: GrantFiled: March 8, 2012Date of Patent: July 23, 2013Assignee: AB ScienceInventors: Alain Moussy, Philippe Reginault, Francois Bellamy, Anne Lermet
-
Publication number: 20120196871Abstract: The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula I: which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.Type: ApplicationFiled: March 8, 2012Publication date: August 2, 2012Applicant: AB SCIENCEInventors: Alain MOUSSY, Philippe REGINAULT, François BELLAMY, Anne LERMET
-
Patent number: 8153792Abstract: The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula (1) which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.Type: GrantFiled: February 13, 2008Date of Patent: April 10, 2012Assignee: AB ScienceInventors: Alain Moussy, Philippe Reginault, François Bellamy, Anne Lermet
-
Patent number: 7976869Abstract: The present invention relates to a novel galenic formulation of fenofibrate for oral administration and to the process for its preparation. According to the invention, the formulation is a tablet obtained by compressing a mixture comprising: a) granules containing: 1 to 5% of a surfactant; micronized fenofibrate; and at least one solid excipient selected from starch, cellulose and derivatives thereof, with the exception of C12 disaccharides, said granules being obtained by granulating the mixture with the aid of an aqueous solution of polyvinylpyrrolidone; b) crosslinked polyvinylpyrrolidone; and c) optionally flow aids or lubricants, the amount of fenofibrate being greater than 50% by weight, expressed relative to the weight of the tablet.Type: GrantFiled: October 21, 2009Date of Patent: July 12, 2011Assignee: Laboratoires Fournier S.A.Inventors: Pascale Blouquin, Philippe Reginault
-
Publication number: 20100121063Abstract: The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula (1) which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.Type: ApplicationFiled: February 13, 2008Publication date: May 13, 2010Applicant: AB SCIENCEInventors: Alain Moussy, Philippe Reginault, Francois Bellamy, Anne Lermet
-
Publication number: 20100040682Abstract: The present invention relates to a novel galenic formulation of fenofibrate for oral administration and to the process for its preparation. According to the invention, the formulation is a tablet obtained by compressing a mixture comprising: a) granules containing: 1 to 5% of a surfactant; micronized fenofibrate; and at least one solid excipient selected from starch, cellulose and derivatives thereof, with the exception of C12 disaccharides, said granules being obtained by granulating the mixture with the aid of an aqueous solution of polyvinylpyrrolidone; b) crosslinked polyvinylpyrrolidone; and c) optionally flow aids or lubricants, the amount of fenofibrate being greater than 50% by weight, expressed relative to the weight of the tablet.Type: ApplicationFiled: October 21, 2009Publication date: February 18, 2010Applicant: LABORATOIRES FOURNIER S.A.Inventors: Pascale Blouquin, Philippe Reginault
-
Publication number: 20040115264Abstract: The invention concerns a novel galenic formulation of fenofibrate for oral administration and its method of preparation. The invention is characterised in that it consists of a tablet obtained by compressing a mixture comprising: a) a granular material containing: 1 to 5% of a surfactant, micronized fenofibrate, at least a solid support selected among starch, cellulose or their derivatives, except C12 disaccharides; said granular material being obtained by granulating the mixture using an aqueous polyvinylpyrrolidone solution; b) crosslinked polyvinylpyrrolidone; c) optionally flow or lubricating agents, the amount of fenofibrate being more than 50 wt. %, expressed relative to the tablet weight. The invention is useful for treating hypercholesterolemia and hypertriglyceridemia.Type: ApplicationFiled: October 16, 2003Publication date: June 17, 2004Inventors: Pascale Blouquin, Philippe Reginault
-
Publication number: 20030082215Abstract: The present invention relates to a pharmaceutical composition for the oral administration of fenofibrate in the form of a preconcentrate capable of forming an oil-in-water microemulsion spontaneously on contact with an aqueous medium, of the type comprising:Type: ApplicationFiled: June 19, 2002Publication date: May 1, 2003Inventors: Josiane Lemut, Pascale Blouquin, Philippe Reginault
-
Patent number: 5561154Abstract: This invention is concerned with a composition and method for the treatment of acute urinary retention, whereby deacetyl moxisylyte or one of its non-toxic salts is administered in a ready to use aqueous solution by the intravenous route to induce a decrease in the urethral contractility.Type: GrantFiled: February 21, 1995Date of Patent: October 1, 1996Assignee: Institut de Recherches Chimiques et Bioloques Appliquees IRCEBAInventors: Fran.cedilla.ois Bellamy, Philippe Reginault, Bernard Rasquin
-
Patent number: 5451609Abstract: This invention is concerned with a novel anti-impotence composition and a novel method for the treatment of impotence, whereby deacetyl moxisylyte or one of its non-toxic salts is administered in a ready to use aqueous solution by injection per intracavernosal route, as a drug inducing a substantially rigid penile erection.Type: GrantFiled: July 27, 1994Date of Patent: September 19, 1995Assignee: Institut De Recherches Chimiques et alInventors: Francois Bellamy, Philippe Reginault, Bernard Rasquin
-
Patent number: 4895726Abstract: The present invention relates to a novel dosage form of fenofibrate containing fenofibrate and a solid surfactant which have been co-micronized.It also relates to the method for the preparation of this dosage form and its use for improving the bioavailabity in vivo.Type: GrantFiled: January 19, 1989Date of Patent: January 23, 1990Assignee: Fournier Innovation et SynergieInventors: Bernard Curtet, Eric Teillaud, Philippe Reginault
-
Patent number: 4842864Abstract: The present invention relates to a novel self-adhesive matrix for the percutaneous administration of an active ingredient. This matrix comprises a combination of the following:(a) 40 to 60 parts by weight of an ethylene/vinyl acetate copolymer material,(b) 40 to 60 parts by weight of a higher aliphatic monoalcohol compound,(c) 1 to 20 parts by weight of a cellulose derivative material,(d) 0.1 to 8 parts by weight of a polyhydric alcohol compound, and(e) 0.01 to 10 parts by weight of an active ingredient which can be administered percutaneously,the weight ratio a+c/b+d being between 0.7 and 1.3.Type: GrantFiled: March 25, 1988Date of Patent: June 27, 1989Assignee: Laboratories D'Hygiene et de DietetiqueInventors: Alain Guillemet, Eric Teillaud, Philippe Reginault
-
Patent number: 4837025Abstract: The present invention relates to a novel self-adhesive matrix for the percutaneous administration of a pharmaceutical active ingredient. This matrix comprises a combination of the following:(a) 30 to 50 parts by weight of an ethylene/vinyl acetate copolymer material,(b) 20 to 45 parts by weight of a higher aliphatic monoalcohol compound,(c) 5 to 20 parts by weight of a cellulose derivative material,(d) 1 to 20 parts by weight of an ester compound of a polyhydric alcohol with a fatty aliphatic acid, and(e) 0.1 to 20 parts by weight of an active ingredient which can be administered percutaneously.Type: GrantFiled: September 22, 1988Date of Patent: June 6, 1989Assignee: Laboratoires D'Hygiene et de DietetiqueInventors: Alain Guillemet, Eric Teillaud, Philippe Reginault, Bruno Bevan